Mucopolysaccharidoses hereditary (overview)E76.2

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Group of rare, autosomal recessive inherited (except mucopolysaccharidosis II = Hunter syndrome with X-linked recessive inheritance), lysosomal storage diseases (see also sphingolipidoses), which are caused by deficiencies of various lysosomal enzymes. The consequences are non-degradable deposition of mucopolysaccharides in tissues and cells and excretion of large amounts of mucopolysaccharides in urine.

ClassificationThis section has been translated automatically.

Classification of mucopolysaccharidoses (MPS) by enzyme defect:

EtiopathogenesisThis section has been translated automatically.

Genetic enzyme defects in the metabolism of mucopolysaccharide protein complexes with intralysosomal accumulation of non-degradable fragments of glycosaminoglycans (thesaurismosis).

Clinical featuresThis section has been translated automatically.

Integument: Skin phenomena are completely in the background of the clinical symptoms. The skin appears thickened and scleroderma-like. There are ivory-coloured, possibly confluent nodules or symmetrical groins between the angles of the scapulae and in the area of the posterior axillary fold. Absence of hair in the area of mons pubis and axillae possible.

Also: skeletal changes, clouding of the cornea, hepatosplenomegaly, vascular changes.

DiagnosisThis section has been translated automatically.

  • Prenatal by amniocentesis.
  • Postpartum: Determination of mucopolysaccharides in urine, detection of the storage of mucopolysaccharides in blood cells as a screening test, enzyme determinations in fibroblasts, leucocytes or serum.

TherapyThis section has been translated automatically.

Not possible.

LiteratureThis section has been translated automatically.

  1. Gupta A et al (2015) Hunter syndrome with late age of presentation: clinical description of a case and review of the literature. BMJ Case Rep doi: 10.1136/bcr-2015-209305.
  2. Fenzl CR et al (2015) Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol 9:1633-1644.
  3. James RA et al.(2016) Australian Paediatric Rheumatology Group. Lysosomal storage disorders: A review of the musculoskeletal features. J Paediatric Child Health 52:262-271.
  4. Kampmann C et al.(2016) Management of Life-Threatening Tracheal Stenosis and Tracheomalacia in Patients with Mucopolysaccharidoses. JIMD RepPMID: 27450368.
  5. Peck SH et al (2016) Pathogenesis and treatment of spine disease in the mucopolysaccharidoses. Mol Genet Metab 118:232-243.
  6. Tran MC et al (2016) Cutaneous Manifestations of Mucopolysaccharidosis. Pediatr Dermatol doi: 10.1111/pde.12971.

Authors

Last updated on: 29.10.2020